NY 303
Alternative Names: NY-303Latest Information Update: 22 Apr 2025
At a glance
- Originator NAYA Biosciences
- Developer NAYA Biosciences; ONK Therapeutics
- Class Antineoplastics; Bispecific antibodies; Immunotherapies; Recombinant fusion proteins
- Mechanism of Action Immunologic cytotoxicity; Natural killer cell stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Liver cancer; Solid tumours
Most Recent Events
- 14 Apr 2025 NAYA Biosciences plans a phase I/IIa trial for Liver cancer (Monotherapy, Second-line therapy or greater) in Israel in second half of 2025
- 31 Oct 2024 Preclinical trials in Liver cancer in USA (Parenteral) prior to October 2024
- 31 Oct 2024 Interim pharmacodynamics data from early research studies in Liver Cancer released by NAYA Biosciences